Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Krishna Schmidt

Physician Assistant Kansas City, MO Physician Assistant

NPI 1013075464 CMS profile 10702234

1010 Carondelet Dr, Suite 125, Kansas City, MO 64114

Open in the dashboard

General payments

$18,190

937 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krishna Schmidt of Kansas City, MO is reported in the CMS Open Payments database as having received $18,190 across 937 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,878 149
2024 General $4,603 194
2023 General $4,170 221
2022 General $3,746 194
2021 General $2,793 179

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krishna Schmidt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Krishna Schmidt were reported at $2,878. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Krishna Schmidt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,793 $132 $37–$438 $132
2022 $3,746 $155 $48–$522 $149
2023 $4,170 $167 $52–$557 $160
2024 $4,603 $178 $55–$600 $164
2025 $2,878 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,159 196 payments
  2. Janssen Biotech, Inc. $2,672 101 payments
  3. Sun Pharmaceutical Industries Inc. $1,570 81 payments
  4. Lilly USA, LLC $1,089 67 payments
  5. LEO Pharma Inc. $882 35 payments
  6. Novartis Pharmaceuticals Corporation $866 43 payments
  7. UCB, Inc. $817 49 payments
  8. Mayne Pharma Inc. $810 43 payments
  9. Amgen Inc. $803 35 payments
  10. E.R. Squibb & Sons, L.L.C. $693 40 payments
  11. Other $4,830 247 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,734 927 payments
  2. Consulting Fee $850 1 payment
  3. Education $582 8 payments
  4. Gift $23 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $2,546 78 payments
  2. RINVOQ $1,399 72 payments
  3. SKYRIZI $1,246 88 payments
  4. TALTZ $961 59 payments
  5. Otezla $803 35 payments
  6. DUPIXENT $705 30 payments
  7. ADBRY $704 29 payments
  8. SOTYKTU $655 38 payments
  9. VTAMA $622 42 payments
  10. OLUMIANT $561 33 payments
  11. Other $8,835 544 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

906

Median for Physician Assistant: 241

Drug cost

$109,020

Median for Physician Assistant: $4,110

Branded share of claims

7.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 15 $85,477
Betamethasone Dipropionate Generic 130 $4,696
Doxycycline Hyclate Generic 155 $3,461
Metronidazole Generic 44 $2,221
Clobetasol Propionate Generic 42 $1,946
Fluorouracil Generic 24 $1,878
Triamcinolone Acetonide Generic 105 $1,305
Fluticasone Propionate Generic 65 $1,271
Tretinoin Generic 11 $1,077
Mycophenolate Mofetil Generic 14 $945

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,253 — —
SKYRIZI
$520 — —
RINVOQ
$323 — —
SOTYKTU
$312 — —
VTAMA
$280 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

937 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record